Cancer treatment including glycolytic inhibitors

Details Cancer treatment including glycolytic inhibitors Cancer treatment including glycolytic inhibitors

2007-01-09

2007-01-09

Maier, Leigh C. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S034000, C514S110000, C514S274000, C514S396000, C514S510000, C514S659000

Reexamination Certificate

active

10401457

ABSTRACT:
Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.

REFERENCES:
patent: 4315001 (1982-02-01), Blough
patent: 4420489 (1983-12-01), Whistler
patent: 4683222 (1987-07-01), Stadler et al.
patent: 4684627 (1987-08-01), LeVeen et al.
patent: 4840939 (1989-06-01), Leveen et al.
patent: 5068186 (1991-11-01), Schlingmann et al.
patent: 5077034 (1991-12-01), Kassis et al.
patent: 5185325 (1993-02-01), Brawn et al.
patent: 5534542 (1996-07-01), O'Halloran et al.
patent: 5565434 (1996-10-01), Barfknecht et al.
patent: 5643883 (1997-07-01), Marchase et al.
patent: 5977327 (1999-11-01), Dziewiszek et al.
patent: 6218435 (2001-04-01), Henry et al.
patent: 6489302 (2002-12-01), Wiessler et al.
patent: 2002/0035071 (2002-03-01), Pitha et al.
patent: 2002/0077300 (2002-06-01), Khosla et al.
patent: 2003/0072814 (2003-04-01), Maibach et al.
patent: 0565785 (1993-10-01), None
patent: 980100107 (1999-11-01), None
patent: 54041384 (1979-04-01), None
patent: WO 01/82926 (2001-11-01), None
patent: WO 02/058741 (2002-08-01), None
Zhang, L. et al “combined anti-fetal liver kinase 1 . . . ” Cancer res. (2002) vol. 62, pp. 2034-2042.
Peter Buhl Jensen et al., Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity, Cancer Chemotherapy and Pharmacology, 1992.
Jisoo Yun et al., Glucose-regulated Stresses Confer Resistance to VP-16 in Human Cancer Cells through a Decreased Expression of DNA Topoisomerase II, Oncology Research, 1995, 583-590, vol. 7, Pergamon Press, USA.
Akihiro Tomida et al., Glucose-Regulated Stresses Induce Resistance to Camptothecin in Human Cancer Cells, Int. J. Cancer, 1996, 391-396, vol. 68, International Union Against Cancer.
Satadal Chatterjee et al., Hypersensitivity to DNA Cross-linking Agents Associated with Up-Regulation of Glucose-regulated Stress Protein GRP78, Cancer Research, Nov. 15, 1997, 5112-5116, vol. 57.
Wing Lam et al., Synergism of energy starvation and dextran-conjugated doxorubicin in the killing of multidrug KB carcinoma cells, Anti Cancer Drugs, 1999, 171-178, vol. 10.
E. M. Bessell et al., The Use of Deoxyfluoro-D-glucopyranoses and Related Compounds in a Study of Yeast Hexokinase Specificity, Biochem. J., 1972, 199-204, vol. 128, Great Britain.
E. M. Bessell et al., Some In Vivo and In Vitro Antitumor Effects of the Deoxyfluoro-D-Glucopyranoses, Europ. J. Cancer, 1973, 463-470, vol. 9, Pergamon Press, Great Britain.
Jae Ho Kim et al., 5-Thio-D-Glucose Selectively Potentiates Hyperthermic Killing of Hypoxic Tumor Cells, Science, Apr. 14, 1978, 206-207, vol. 200.
Beverly A. Teicher et al., Classification of Antineoplastic Agents by their Selective Toxicities toward Oxygenated and Hypoxic Tumor Cells, Cancer Research, Jan. 1981, 73-81, vol. 41.
J. R. Colofiore et al., Enhanced Survival of Adriamycin-treated Chinese Hamster Cells by 2-Deoxy-D-glucose and 2,4-Dinitrophenol, Cancer Research, Oct. 1982, 3934-3940, vol. 42.
Kiyofumi Yamanishi, Effects of Valinomycin on Hexose Transport and Cellular ATP Pools in Mouse Fibroblasts, Journal of Cellular Physiology, 1984, 163-171, vol. 119.
J. Shen et al., Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells, Proc. Natl. Acad. Sci. USA, May 1987, 3278-3282, vol. 84, USA.
Christine S. Hughes et al., Resistance to Etoposide Induced by Three Glucose-regulated Stresses in Chinese Hamster Ovary Cells, Cancer Research, Aug. 15, 1989, 4452-4454, vol. 49.
Karczmar et al.,Cancer Res., Jan. 1, 1992, 52:71-6.
Juling-Pohlit et al.,Strahlenther. Onkol., 1990,166(1):6-9.
Saydjari et al.,Invest. New Drugs, 1989, 7:131-8.
Mack et al.,Eur J Cancer Clin. Oncol., Sep. 1988, 24(9):1433-7.
Kern et al.,Surgery, Aug. 1987, 102(2):380-5.
Gridley et al.,Int. J. Rad. Oncol. Biol. Phys., Mar. 1985, 11:567-74.
Dills et al.,J. Nutr., 1984, 114(11):2097-106.
Tannock et al.,Cancer Res., Mar. 1983, 43(3):980-3.
Bernal et al.,Science, Oct. 14, 1983, 222:169-72.
Purohit,Int. J. Rad. Oncol. Biol. Phys., Mar.-Apr. 1982, 8(3-4):495-9.
Laszlo et al.,JNCI, Feb. 1960, 24 (2):267-279.
Ball et al.,Cancer Res., Apr. 1957, 17(3):235-9.
Sokoloff et al.,AMA Arch. Path., Jun. 1955, 59(6):729-32.
Woodward et al.,Notes Biochem. Res. Found., 2-Desoxy-D-Glucose as an inhibitor of anaerobic glycolysis in tumor tissue.
Abbink et al.,J. Card. Pharml., 2001, 37:94-100.
Adler et al.,Neuropsychopharmacology, 2000, 22(5):545-50.
George et al.,Alcohol Clin. Exp. Res., May/Jun. 1994, 18(3):685-91.
Breier et al.,Arch. Gen. Psychiatry, Jul. 1993, 50:541-50.
Breier et al.,Psychopharmacology, 1991, 104:479-84.
Breier,Biol. Psychiatry, 1989, 26:438-62.
Fagius et al.,Am. J. Physiol., 1989, 256(6.1):E714-20.
Hansen et al.,Ped. Res., 1984, 18(5):490-5.
Hansen et al.,Metabolism, Oct. 1983, 32(10):960-70.
Kerr et al.,Metabolism, Oct. 1983, 32(10):951-9.
Thompson et al.,Metabolism, Oct. 1981, 30(10):1015-20.
Thompson et al.,Am. J. Physiol., Sep. 1980, 239(3):291-295.
Thompson et al.,Science, Dec. 9, 1977, 198:1065-8.
Woolf et al.,J. Clin. Endocr. Metab., 1977, 45(3):377-83.
Weber et al.,J. Surg. Res., 1975, 18:491-5.
Burckhardt et al.,Digestion, 1975, 12:1-8.
Gough et al.,Gut, 1975, 16:171-6.
Brodows et al.,J. Clin. Invest., Aug. 1973, 52:1841-4.
Sizonenko et al.,Ped. Res., 1973, 7:983-93.
Peytremann et al.,Europ. J. Clin. Invest., 1972, 2:432-8.
Freinkel et al.,NEJM, Oct. 26, 1972, 287(17):841-5.
Lipman et al.,Metabolism, 1970, 19(11):980-7.
Thomas et al.,Gut, 1968, 9:125-8.
Grasso et al.,J. Clin. Endocr., 1968, 28:535-42.
Wegienka et al.,Metabolism, Mar. 1967, 16(3):245-56.
Wegienka et al.,J. Clin. Endocr., Jan. 1966, 26:37-45.
Duke et al.,Lancet, Oct. 30, 1965, 871-6.
Harlan et al.,J. Clin. Endocrinol. Metab., Jun. 1963, 23:41-9.
Laszlo et al.,J. Clin. Invest., Jan. 1961, 40:171-6.
Landau et al.,JNCI, Sep. 1958, 21(3):485-494.
Mohanti et al.,Int. J. Rad. Oncol. Biol. Phys., 1996, 35(1):103-11.
Blough et al., JAMA, Jun. 29, 1979, 241(26): 2798-2801.
Song et al.,Cancer Res., Dec. 1978, 38: 4499-4503.
Song et al.,Br. J. Cancer, 1978, Suppl. III:136-140.
Song et al.,JNCI, Sep. 1976, 57(3): 603-605.
Clavo et al.,J. Nuc. Med., Sep. 1995, 36(9):1625-1632.
Mesmer et al.,Biochem. Mol. Biol. Int., Oct. 1996, 40(2): 217-33.
Liu et al.,Biochem. Pharmacol., 2002, 64:1745-51.
Aft et al.,Br. J. Cancer, 2002, 87:805-12.
Chandna et al.,Rad. Res., 2002, 157:516-25.
Mese et al.,Anticancer Res., 2001, 21:1029-33.
Liu et al.,Biochemistry, May 8, 2001, 40: 5542-7.
Reinhold et al.,Oncol. Rep., 2000, 7:1093-97.
Yamada et al.,Cancer Chemother. Pharmacol., 1999, 44:59-64.
Dwarakanath et al.,Int. J. Rad. Oncol. Biol. Phys., 1999, 43(5):1125-33.
Belfi et al.,BBRC, 1999, 257:361-8.
Kalia,Indian J. Med Res., May 1999, 109:182-7.
Haga et al.,Int. J. Cancer, 1998, 76:86-90.
Malaisse et al.,Cancer Lett., Mar. 13, 1998, 125(1-2):45-9.
Chatterjee et al.,Cancer Res., Nov. 15, 1997, 57:5112-16.
Kaplan et al.,Cancer Res., Apr. 15, 1997, 57:1452-9.
Vivi et al.,Breast Cancer Res. Treat., 1997, 43:15-25.
Tomida et al.,Oncogene, 1996, 13:2699-2705.
Kraegen et al.,Am. J. Physiol., 1985, 248: E353-E362.
Yun et al.,Oncology Res., 1995, 7(12):583-590.
Halicka et al.,Cancer Res., Jan. 15, 1995, 55:444-9.
Schaider et al.,J. Cancer Res. Clin. Oncol., 1995, 121(4):203-10.
Griffiths et al.,Int. J. Biochem., 1993, 25(12):1749-55.
Kalia,Indian J. Exp. Biol., Apr. 1993, 31:312-5.
Jha et al.,Int. J. Rad. Biol., 1993, 63(4):459-67.
Haberkorn et al.,J. Nucl. Med., Nov. 1992, 33(11):1981-7.
Cay et al.,Cancer Res., Oct. 15, 1992, 52:5794-6.
Kaplan et al.,Cancer Res., Mar. 15, 1991, 51:1638-44.
Kaplan et al.,Cancer Res., Feb. 1, 1990, 50:544-51.
Dwarakanath et al.,Indian J. Med. Res., Jun. 1990, 92:183-8.

Affiliated with

Also associated with

Rating

Cancer treatment including glycolytic inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer treatment including glycolytic inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment including glycolytic inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3720977